

INVESTMENT OBJECTIVE

To achieve capital appreciation on an absolute and relative basis over the medium to long-term horizon through investment in Swiss equities with a focus on innovative companies that are leaders in their markets profile.

PORTFOLIO REVIEW

The Swiss index has been very volatile this year, with each passing month little resembling the prior one, to say the least. Against a highly uncertain backdrop, the market was eagerly awaiting listed Swiss companies' first half numbers. This earnings season is crucially important, as it often constitutes the first indication that companies – at least the smaller ones – provide since their prior year results, and thus sets the tone for the rest of the year. Disappointed expectations combined with low summer trading volumes can sometimes form an explosive cocktail. Nothing of the sort happened this year, and results were, on the whole, rather good, enabling a 2.7% SPI gain. Like in other markets, small- and mid-caps outperformed slightly, up 3.3%.

The Protea BAM Swiss Equities thus posted a 4.2% rebound in July, bringing its year-to-date performance to 11.0%.

Among the fund's top monthly performers figure Roche (+15%), Belimo (+17%), Lonza (+20%), Sandoz (+17%) and Accelleron (+24%).

Up 33% since its early May low, Roche finally had some good news to share with the market after a series of setbacks. Not only did solid 2nd quarter results allow management to slightly up its full-year earnings guidance, but several pieces of good news during the month regarding its anti-obesity franchise (acquired from Carmot in 2023) put the Basel-based giant back in the spotlight.

Lonza also released numbers that positively surprised the market, in particular a larger-than-expected increase in its EBITDA margin, thanks to strong growth in its more profitable biologics business, which should lead to upward analyst revisions.

We must also flag Belimo's excellent report. Despite a sluggish construction sector and tough base effects, the company was able to increase its 2024 sales growth projection, now seen above the 9% long-term target (in local currencies), thanks notably to very strong demand in its "data centres" business.

Finally, a word on Accelleron's third upward earnings guidance since having been spun-off from ABB, underpinning a gain of almost 70% year-to-date.


Conversely, the largest declines were posted by VAT (-14%), Galderma (-7%), Richemont (-5%) and Nestlé (-3%).

Richemont, like all luxury-related stocks, has been under pressure in recent weeks because of continued sluggish growth in China and a slowdown in US consumers' propensity to spend. That said, among the luxury goods players, we consider Richemont to be very well positioned thanks to its jewellery business, much more resilient in times of crisis.

As for VAT, a key supplier to the semiconductor industry, it suffered a correction in sync with the sector, after hitting a high mid-July.

NET PERFORMANCE AND ANNUAL PERFORMANCE IN CHF

10.06.2021 - 31.07.2024



	Fund	MSCI Switzerland 10-40	+/-
1 Month	4.2%	2.9%	1.3%
3 Months	8.8%	9.1%	-0.3%
YTD	11.0%	13.1%	-2.1%
Since inception	0.9%	9.6%	-8.6%

Source: All data and graphs throughout the document from Bruellan.

Past performance may not be a reliable guide to future performance. All forms of investment involve risk.

The benchmark index is the MSCI Switzerland 10-40.

Please refer to the end of the document mentioned for performance comparison purposes.

RISK & REWARD



FUND FACTS

Domicile	Luxembourg (UCITS)
Inception date	10 June 2021
Currency	CHF
Lead Manager	Anick Baud
Co-Manager	Florian Marini CFA, CMT
Fund size*	CHF 29 Millions
Liquidity (sub./red.)	Daily
Min. Investment	Instit.: 1 million CHF

Entry/exit fees	0.0% / 0.0%
Management fees	0.8%
Performance fees	20%
High Water Mark	Yes
Benchmark	MSCI Switzerland 10-40
ISIN	Instit.: LU2264701074

Bloomberg	Instit.: PRPSEIC LX
-----------	---------------------

NAV	Instit: 100.92
-----	----------------


* the total strategy size is CHF 60 millions

Not all the costs are presented, further information can be found in the prospectus or equivalent.


STATISTICS

	Fund	MSCI Switzerland 10-40
Leading PE	22.6	16.0
EV/EBITDA	20.2	12.7
P/Book	5.4	1.7
Dividend Yield	2.2%	2.7%
ROE	22.6%	9.8%
Debt/Equity	56.2%	57.3%
Interest Coverage	15.5	8.0
Beta	1.1	1.0
Volatility	17.3%	13.5%

ALLOCATION BY MARKET CAP



ALLOCATION BY SECTOR



FUND COMPLEMENTARY DETAILS

Administrator	Fund Partner Solutions SA
Representative in Switzerland	FundPartner Solutions (Suisse) SA
Investment Manager	Bruellan SA
Paying agent in Switzerland	Banque Pictet & Cie SA
Auditor	Deloitte Audit SARL
Custodian	Bank Pictet & Cie (Europe) AG, Succursale de Luxembourg

TOP 10 HOLDINGS

	Sector	Weight
ROCHE HOLDING AG-GENUSSCHEIN	Health Care	10.1%
NOVARTIS AG-REG	Health Care	9.2%
NESTLE SA-REG	Consumer Staples	8.5%
SANDOZ GROUP AG	Health Care	4.7%
ZURICH INSURANCE GROUP AG	Financials	4.3%
SIKA AG-REG	Materials	3.8%
CIE FINANCIERE RICHEMO-A REG	Consumer Discretionary	3.5%
GIVAUDAN-REG	Materials	3.5%
FISCHER (GEORG)-REG	Industrials	3.4%
BELIMO HOLDING AG-REG	Industrials	3.4%
Total		54.3%

Total number of Holdings

27

CONTACT

BRUELLAN SA
Rue Pécolat 1
CH-1201 Genève
Tél: +41 22 817 18 55
bam@bruellan.ch

Disclaimer. Bruellan SA has a FINMA authorisation as a collective asset manager. This publication is a promotional document within the meaning of art. 68 LSFIn, it is not independent research. It is solely intended to provide information on the funds in question and does not constitute an offer to buy or sell, investment advice or a recommendation regarding investment or other decisions. The funds may be subject to sales restrictions applicable to certain countries or individuals. It is the responsibility of each investor to be aware of the terms and conditions applicable to each product. This publication is directed only at persons authorised to receive it under the regulations in force in their country of domicile.

The information contained herein is based on sources believed to be reliable. This is a marketing communication. Bruellan cannot guarantee its completeness and accuracy and accepts no liability for any damage that may result from actions taken on the basis of the information published in this document. The information reflects the situation on the day of publication. We have classified this product as 5 out of 7, which is a medium - high risk class. Please refer to the prospectus for more information on the specific risks relevant to this product not included in the summary indicator.

Investment decisions should always be made on the basis of a detailed source of information, in particular the fund prospectus. The prospectus, the articles of association, the key information document, the subscription form and the latest annual and semi-annual reports can be obtained (free of charge) from the Swiss representative, Fund Partner Solutions (Suisse) SA, 60, route des Acacias, 1211 Geneva. Please refer to the prospectus and information document of the fund before making any final investment decisions. You can obtain a summary of investors rights to the following link:

<https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-Investors-rights.pdf>. The decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in its prospectus. Information on sustainability-related aspects provided in relation to the promoted fund could be found on the following link:

<https://assetservices.group.pictet/asset-services/esg-disclosures?isin=LU1118008553>. Incorporation of extra-financial risks into the investment decision process may result in underweighting of profitable investments from the sub-fund's investment universe and may also lead the management of the sub-fund to underweight investments that will continue to perform. The Fund has been classified as a financial product subject to Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial sector (the "SFDR"). The Fund promotes, among other characteristics, environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices. Performance disclosures: the published performance represents past data. Past performance may not be a reliable guide to future performance. There is no guarantee that the same yields will be obtained in the future. The value and income of any of your investments may fluctuate with market conditions and may lose some or all its value. The fund may be affected by changes in currency exchange rates, which can have an adverse effect on the value or income of the fund. Future performance is also subject to taxation which depends on the personal situation of each investor and which may change in the future. : All performance data are based on net performance and take no account of commissions, fees or other costs charged when units are issued and redeemed.